Benzinga | Nov 10, 2020 08:18AM EST

Raymond James Maintains Outperform on Arcturus Therapeutics, Lowers Price Target to $73

Raymond James maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and lowers the price target from $79 to $73.